Biogen Idec and Samsung Bioepis announce agreement to market anti-TNF biosimilar product candidates in Europe
17 December 2013 | By Biogen Idec
Biogen Idec opts-in to commercialization opportunity with joint venture partner...
List view / Grid view
News
GSK initiates voluntary open offer to increase stake in its pharmaceuticals subsidiary in India
16 December 2013 | By GlaxoSmithKline
GSK intends to keep the Company publicly-listed...
Hepatitis C: Phase III data show Boehringer Ingelheim’s faldaprevir* is effective even in patients with common drug-resistant viral variant
16 December 2013 | By Boehringer Ingelheim,
"These data are encouraging as they demonstrate that HCV genotype-1 infected patients irrespective of the presence of the common HCV Q80K variant..."
Daiichi Sankyo launches four new generic drugs through its Daiichi Sankyo Espha Subsidiary
13 December 2013 | By Daiichi Sankyo
Daiichi Sankyo Espha launched two new generic drugs with two new active ingredients and two generic drugs with an additional standard...
AstraZeneca announces top-line results from phase III monotherapy study of lesinurad in gout patients
13 December 2013 | By AstraZeneca
Lesinurad is an investigational agent being studied as a selective uric acid re-absorption inhibitor that inhibits the URAT1 transporter...
IFPAC-2014 Show Preview – QbD & PAT
12 December 2013 | By IFPAC
IFPAC is the essential meeting place for the latest developments in Process Analytical Technology...
FDA Advisory Committee votes on investigational medicine metreleptin
12 December 2013 | By AstraZeneca
Advisory Committee recommends metreleptin for the treatment of paediatric and adult patients with generalised lipodystrophy...
Merck Statement on FDA Advisory Committee for GRASTEK® (Timothy Grass Pollen Allergen Extract), Merck’s Investigational Sublingual Allergy Immunotherapy Tablet
12 December 2013 | By Merck
GRASTEK is the proposed trade name for the company’s investigational sublingual tablet for the treatment of Timothy grass induced allergic rhinitis...
FDA advisory committee recommends the investigational SGLT2 inhibitor dapagliflozin for treatment of type 2 diabetes in adults
12 December 2013 | By AstraZeneca
Dapagliflozin is being reviewed by the FDA for use as monotherapy, and in combination with other antidiabetic agents...
Bridgepoint Development Capital to acquire Quotient Clinical
11 December 2013 | By KDM Communications
Quotient Clinical has been acquired from the Quotient Bioresearch Group by Bridgepoint Development Capital for an undisclosed sum...
GSK announces £200 million investment in UK advanced manufacturing and science
11 December 2013 | By GlaxoSmithKline
Manufacturing sites in Ware, Hertfordshire and Worthing, Sussex will be upgraded with new state-of-the-art equipment...
Professor Moshe Many to leave post as Vice Chairman effective January 1, 2014, will remain a member of the board
10 December 2013 | By Teva
Amir Elstein to succeed Professor Moshe Many...
Novo Nordisk reported to the police by the Danish Financial Supervisory Authority for violating disclosure obligation
10 December 2013 | By Novo Nordisk
The reporting relates to the company’s receipt of a Complete Response Letter from the US Food and Drug Administration...
Merck advances development program for investigational Alzheimer’s Disease Therapy, MK-8931
10 December 2013 | By Merck
The DMC recommendation was made following a planned analysis of interim safety data that included a safety cohort of 200 patients treated with MK-8931 for at least 3 months...
New data analyses show consistent efficacy and safety profile of Pradaxa® in broad range of patients with acute deep vein thrombosis or pulmonary embolism
10 December 2013 | By Boehringer Ingelheim
The efficacy and safety profile of Pradaxa® (dabigatran etexilate) was maintained regardless of patient characteristics...
